Mesoblast (ASX:MSB)
ASX announcement history & article coverage
Transparent by design.
Announcments by Mesoblast (ASX:MSB) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
MSB Annual Financial Results and Operational Update
Mesoblast reports US$120M revenue with strong Ryoncil launch and Phase 3 trial completion
Annual Financial Results Presentation
Mesoblast reports US$115M revenue from RYONCIL launch, advances Phase 3 trials for chronic low back pain and heart failure
Preliminary Final Report including Appendix 4E
Mesoblast reports FY26 revenue growth to $120M on Ryoncil® sales, advances clinical pipeline, reduces net loss
Appendix 3Y - Philip Krause
Notification regarding unquoted securities - MSB
Mesoblast 2026 Full Year Financial Results Webcast
Mesoblast to Host Webcast on FY 2026 Financial Results and Operational Highlights
Major Milestone Treatment Completed in P3 Trial for CLBP
Mesoblast completes patient treatment in pivotal Phase 3 trial for chronic low back pain
Becoming a substantial holder
Ceasing to be a substantial holder
Becoming a substantial holder
Ceasing to be a substantial holder
Becoming a substantial holder
Quarterly Activities/Appendix 4C Cash Flow Report
Mesoblast reports US$115M Ryoncil revenue first year post-FDA, expands indications and advances trials
Ceasing to be a substantial holder
Ceasing to be a substantial holder
Mesoblast CEO Makes Investment to Increase Share Ownership
Appendix 3Y - Silviu Itescu
Notification regarding unquoted securities - MSB
Application for quotation of securities - MSB
Notification of cessation of securities - MSB
Notification regarding unquoted securities - MSB
Application for quotation of securities - MSB
Notification regarding unquoted securities - MSB
Appendix 3Y - Silviu Itescu
Pivotal Phase 3 Trial in CLBP Achieves 300 Treated Patients
Mesoblast completes patient target in Phase 3 trial for chronic low back pain
Ryoncil Q4 Net Revenue of US$36M and US$115M for Full Year
Mesoblast reports US$115M full-year revenue for Ryoncil® with strong growth outlook
Receives FDA BLA Filing Number and Requests Modular Review
Mesoblast Receives FDA BLA Filing Number for Rexlemestrocel-L in End-Stage Heart Failure Patients with LVADs
Becoming a substantial holder
Ceasing to be a substantial holder
Mesoblast Draws US$50M from Five-Year Non-Dilutive Facility
Mesoblast draws US$50 million from five-year non-dilutive facility to retire short-term debt
Becoming a substantial holder